Crosspoint Capital Strategies’s Teva Pharmaceuticals TEVA Stock Holding History

Crosspoint Capital Strategies’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,800	Closed	-$118K	–	737
2015 Q4	$118K	Sell	1,800 -219	-11%	-$13.5K	0.03%	298
2015 Q3	$114K	Sell	2,019 -781	-28%	-$50.6K	0.13%	154
2015 Q2	$165K	Sell	2,800 -700	-20%	-$43.2K	0.05%	214
2015 Q1	$218K	Buy	3,500 +1,500	+75%	+$87.2K	0.11%	130
2014 Q4	$115K	Buy	2,000 +1,950	+3,900%	+$109K	0.04%	266
2014 Q3	$3K	Buy	+50	New	+$2.65K	﹤0.01%	448

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Crosspoint Capital Strategies's TEVA Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 1,800 shares — an estimated $118K sold.

Crosspoint Capital Strategies first reported a position in TEVA in Q3 2014 and held it in 6 quarters. The position peaked at $218K in Q1 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Crosspoint Capital Strategies reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 1,800 Teva Pharmaceuticals shares in Q1 2016, an estimated $118K.
Crosspoint Capital Strategies first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 6 quarters.
Crosspoint Capital Strategies's Teva Pharmaceuticals position peaked at $218K in Q1 2015.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.